Is it Worth Adding Boston Scientific Stock to Your Portfolio Now?

Boston Scientific (BSX) demonstrates robust operational momentum, driven by market share gains in its MedSurg segment (endoscopy, neuromodulation, urology) and a 24% Q1 2025 sales increase for its WATCHMAN device. Recent strategic acquisitions added 400 basis points to Q1 sales, contributing to 18.2% organic revenue growth and propelling a 33.6% share rally over the past year, significantly outperforming the broader market. However, the company faces a projected 50-basis point headwind on 2025 revenues due to currency fluctuations, given its substantial international sales exposure.

Analysis

Boston Scientific (BSX) is demonstrating robust fundamental strength, evidenced by its 33.6% share price rally over the past year, which significantly outpaces the S&P 500's 10.1% gain. This performance is underpinned by a multi-faceted growth strategy. The core MedSurg segment is consistently gaining market share, driven by product strength in endoscopy, neuromodulation, and urology. Furthermore, the company's WATCHMAN device is a key growth engine, with sales increasing 24% year-over-year in Q1 2025, boosted by favorable new DRG rules and strong adoption of next-generation models. Critically, Boston Scientific's accretive acquisition strategy is proving successful, with recent buyouts contributing 400 basis points to Q1 sales and helping to achieve an 18.2% organic revenue growth rate. While the company has consistently beaten earnings estimates with an average surprise of 8.79%, it faces a specific headwind from currency fluctuations, projecting a 50-basis point negative impact on 2025 revenues due to its 40% international sales exposure.

Key Decisions for Investors

• Given the company's strong execution across organic growth, product innovation, and M&A integration, investors could view the current momentum and positive Zacks Rank #2 (Buy) as supportive of a bullish thesis.
• It is critical to monitor the sales velocity of the WATCHMAN franchise and the successful closing and integration of the pending SoniVie and Intera Oncology acquisitions as primary catalysts for future growth.
• While the operational outlook is strong, investors should factor the guided 50-basis point currency headwind into 2025 revenue models and monitor for any escalation in foreign exchange volatility.